strain-details - INFRAFRONTIER

Information from provider

Status	Available to order
EMMA ID	EM:04509
International strain name	STOCK Mr1^tm1Gfn Tcra^tm1Mjo Tap1^tm1Arp Cd74^tm1Doi Tg(Tcra-V19-J33)#Lantz Tg(Tcrb-V6)#Lantz/Orl
Alternative name	iVa19/Vb6 Calpha ko TAP-/- ii -/- MR1+/-
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Mr1^tm1Gfn,
Gene/Transgene symbol	Mr1

Provider	Olivier Lantz
Provider affiliation	immunology, Institut Curie
Genetic information	The VJ alpha (Va19-Ja33) and beta (Vb6) of MAIT cell hybridoma have been inserted into the shuttle vector described by Patten et al (J Immunol. 1993 Mar 15;150(6):2281-94.). The Va19-Ja33 transgene was introduced into B6 x DBA/2 eggs before being backcrossed 10 times to C57BL/6J. The Vb6 transgene was injected into C57BL/6 eggs.
Phenotypic information	The strain expresses a monoclonal population of MAIT cells.
Breeding history	It is a double transgenic (independently injected and thus not linked). It is immunodeficient and requires homozygous breeding.
References	Stepwise development of MAIT cells in mouse and human.;Martin Emmanuel, Treiner Emmanuel, Duban Livine, Guerri Lucia, Laude Hélène, Toly Cécile, Premel Virginie, Devys Anne, Moura Ivan C, Tilloy Florence, Cherif Stéphane, Vera Gabriella, Latour Sylvain, Soudais Claire, Lantz Olivier, ;2009;PLoS biology;7;e54; 19278296
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	yes
Immunocompromised	yes

Information from EMMA

Archiving centre	Institut de Transgenose, INTRAGENE, Orléans, France
Breeding at archiving centre	Males transgenic for Tg(Tcra-V19-J33)#Lantz (iVa) and Tg(Tcrb-V6)#Lantz (Vb6), homozygous knock-out for Tap1, Cd74 (ii) and Tcra (C alpha), homozygous or heterozygous knock-out for Mr1. For cryoarchiving females and males were crossed together.

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Immunodeficiency by defective expression of MHC class I / Orphanet_34592

MGI phenotypes (allele matching)

abnormal dendritic cell antigen presentation / MGI
abnormal antigen presentation / MGI
abnormal level of surface class II molecules / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
increased susceptibility to experimental autoimmune encephalomyelitis / MGI
abnormal B cell physiology / MGI
abnormal T cell number / MGI
decreased susceptibility to bacterial infection / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
increased T-helper 1 cell number / MGI
decreased susceptibility to bacterial infection induced morbidity/mortality / MGI
abnormal antigen presentation via MHC class I / MGI
defective assembly of class I molecules / MGI
defective intracellular transport of class I molecules / MGI
decreased level of surface class I molecules / MGI
decreased cytotoxic T cell cytolysis / MGI
absent CD8-positive, alpha-beta T cells / MGI
abnormal lymphocyte physiology / MGI
decreased double-negative T cell number / MGI
abnormal T cell physiology / MGI
decreased susceptibility to autoimmune diabetes / MGI
immune system phenotype / MGI
increased activated T cell number / MGI
rectal prolapse / MGI
abnormal colon morphology / MGI
abnormal intestinal mucosa morphology / MGI
enlarged spleen / MGI
spleen hyperplasia / MGI
colitis / MGI
increased T cell number / MGI
diarrhea / MGI
decreased T cell proliferation / MGI
increased gamma-delta T cell number / MGI
enlarged mesenteric lymph nodes / MGI
abnormal neuron proliferation / MGI
abnormal thymus cortex morphology / MGI
increased immunoglobulin level / MGI
increased IgE level / MGI
abnormal immune system organ morphology / MGI
increased autoantibody level / MGI
increased anti-double stranded DNA antibody level / MGI
increased anti-nuclear antigen antibody level / MGI
increased B cell number / MGI
abnormal T cell morphology / MGI
small Peyer's patches / MGI
increased IgG1 level / MGI
abnormal splenic cell ratio / MGI
absent thymus medulla / MGI
enlarged thymus cortex / MGI
abnormal kidney morphology / MGI
increased urine protein level / MGI

Literature references

Stepwise development of MAIT cells in mouse and human.;Martin Emmanuel, Treiner Emmanuel, Duban Livine, Guerri Lucia, Laude Hélène, Toly Cécile, Premel Virginie, Devys Anne, Moura Ivan C, Tilloy Florence, Cherif Stéphane, Vera Gabriella, Latour Sylvain, Soudais Claire, Lantz Olivier, ;2009;PLoS biology;7;e54; 19278296

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*

Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

STOCK Mr1tm1Gfn Tcratm1Mjo Tap1tm1Arp Cd74tm1Doi Tg(Tcra-V19-J33)#Lantz Tg(Tcrb-V6)#Lantz/Orl